Galectin 3 (LGALS3)

Subscribe to Selected New Research on Galectin 3

586 relevant articles (14 outcomes, 118 trials/studies) found for this Bio-Agent

Description: A multifunctional galactin initially discovered as a macrophage antigen that binds to IMMUNOGLOBULIN E, and as 29-35-kDa lectin that binds LAMININ. It is involved in a variety of biological events including interactions with galactose-containing glycoconjugates, cell proliferation, CELL DIFFERENTIATION, and APOPTOSIS.

Also Known As:

LGALS3; CBP-30; CBP-35; CBP35; Carbohydrate-Binding Protein 35; Epsilon-Binding Protein; Galectin-3; HL-29; IgE Binding Protein; IgEBP; L-29 Lectin; L-31; L-34; L30 Lectin; Macrophage-2 Antigen; Antigen, Mac-2; Antigen, Macrophage-2; Binding Protein, IgE; Carbohydrate Binding Protein 35; Epsilon Binding Protein; L 29 Lectin; Mac 2 Antigen; Macrophage 2 Antigen; Protein, IgE Binding; Mac-2 Antigen

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Experts

1.	Raz, Avraham: 15 articles (12/2007 - 05/2003)
2.	Gabius, Hans-Joachim: 12 articles (09/2008 - 01/2003)
3.	Liu, Fu-Tong: 12 articles (08/2008 - 02/2002)
4.	Decaestecker, Christine: 8 articles (09/2008 - 05/2003)
5.	Salmon, Isabelle: 7 articles (08/2008 - 01/2003)
6.	Papotti, Mauro: 7 articles (08/2005 - 10/2002)
7.	Kiss, Robert: 6 articles (09/2005 - 01/2003)
8.	Raz, A: 6 articles (03/2005 - 07/2000)
9.	Fukumori, Tomoharu: 5 articles (02/2008 - 01/2004)
10.	Kaltner, Herbert: 5 articles (09/2005 - 01/2003)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2008 - "At 6 hrs post-injection galectin-3 expressing tumors were correctly visualized, while the whole-body activity had essentially cleared. " 03/01/2009 - "In the current study we examined the possibility of urinary galectin-3 levels to stage cancer disease and to follow up therapy. " 01/01/2009 - "Altered expression of galectin-3 has been described in many cancers, and studies of cancer cell lines have implicated this lectin in various aspects of the tumorigenic cascade. " 09/01/2008 - "Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics: an immunohistochemical and RT-PCR study." 07/01/2008 - "CONCLUSION: The recombinant lentiviral U6 plasmid for RNAi of Galectin-3 gene has been successfully constructed, which provides the basis for further study of the role of galectin-3 gene in tumor cells." Order ALL the reference details at left...
2.	Adenoma (Adenomas) 12/01/2008 - "Two cases with follicular adenomas were negative for Galectin-3. " 03/01/2007 - "All adenomas resulted negative for galectin-3 immunostaining. " 09/01/2005 - "But all three eosinophilic follicular adenomas were diffusely or focally positive for galectin-3. " 02/01/2005 - "Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia." 11/01/2004 - "However, a large proportion of follicular adenomas (72%) and multinodular goitres (57%) also expressed galectin-3. " Order ALL the reference details at left...
3.	Carcinoma (Carcinomatosis) 08/01/2005 - "Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma." 11/01/2002 - "Furthermore, studies of RPMI-2650 variants suggest that galectin-3 expression correlates with nasal carcinoma cell invasiveness. " 07/20/2000 - "In our study, we have examined the expression of galectin-3 in a population of 145 prostate carcinoma samples using immunohistochemistry. " 07/01/2009 - "Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis." 01/01/2009 - "Galectin-3 expression was more frequent in clear cell carcinomas, serous tumours and mucinous tumours than in endometrioid and transitional tumours. " Order ALL the reference details at left...
4.	Thyroid Neoplasms (Thyroid Cancer) 07/01/2006 - "CONCLUSIONS: Our study confirms the high diagnostic value of galectin-3 in papillary thyroid carcinoma and reveals the similar efficiency of CA50. " 08/01/2005 - "As reported in several studies, galectin-3 is highly expressed in papillary thyroid carcinoma, but its expression has not been investigated in papillary microcarcinoma, which is a variant of papillary thyroid carcinoma. " 10/01/2004 - "In this retrospective histologic study, galectin-3 had a sensitivity of 92% (22/24) for papillary thyroid carcinoma and 44% (4/9) for follicular thyroid carcinoma. " 04/01/2003 - "Our study suggests that the variable pattern of galectin-3 expression may reflect a difference in biologic behavior between HTT and papillary thyroid carcinoma." 04/01/2003 - "In this study we compared galectin-3 expression in a number of different thyroid neoplasms to gain insight into the biologic behavior of HTT. " Order ALL the reference details at left...
5.	Neoplasm Metastasis (Metastasis) 08/01/1998 - "Reduction in galectin 3 levels was associated with a marked decrease in liver colonization and spontaneous metastasis by LSLiM6 and HM7 cells, whereas up-regulation of galectin 3 resulted in increased metastasis by LS174T cells. " 05/01/2009 - "Galectin-3 on vascular endothelium has been shown to facilitate lung specific metastasis. " 12/28/2008 - "Except for the negative control group, the expression of galectin-3 in liver metastases of the other 4 groups showed no significant difference. " 12/28/2008 - "Expression of galectin-3 in liver metastasis was detected by immunohistochemistry. " 08/01/2008 - "In the positive control and the MCP-treated groups, the expression of galectin-3 in the liver metastases showed no significant differences (P>0.05). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Galectins (Galectin)
2.	Messenger RNA (mRNA)
3.	Mucins
4.	Paclitaxel (Taxol)
5.	Leucine (L-Leucine)
6.	Selectins
7.	Galectin 1 (LGALS1)
8.	Laminin (Merosin)
9.	Complementary DNA (cDNA)
10.	beta Catenin

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Thyroidectomy
4.	Transplants (Transplant)
5.	Carotid Endarterectomy

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>